
Jose Alvarez-Sabin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6250052/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke. New England Journal of Medicine, 2004, 351, 2170-2178.	13.9	1,006
2	Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke. Circulation, 2003, 107, 598-603.	1.6	494
3	Microbubble Administration Accelerates Clot Lysis During Continuous 2-MHz Ultrasound Monitoring in Stroke Patients Treated With Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 425-429.	1.0	431
4	Increased Brain Expression of Matrix Metalloproteinase-9 After Ischemic and Hemorrhagic Human Stroke. Stroke, 2006, 37, 1399-1406.	1.0	382
5	Tandem Internal Carotid Artery/Middle Cerebral Artery Occlusion. Stroke, 2006, 37, 2301-2305.	1.0	350
6	Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. Stroke, 2008, 39, 2280-2287.	1.0	264
7	Effects of Admission Hyperglycemia on Stroke Outcome in Reperfused Tissue Plasminogen Activator–Treated Patients. Stroke, 2003, 34, 1235-1240.	1.0	235
8	Thrombolysis-Related Hemorrhagic Infarction. Stroke, 2002, 33, 1551-1556.	1.0	224
9	Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet, The, 2012, 380, 349-357.	6.3	215
10	Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurology, The, 2013, 12, 689-705.	4.9	215
11	Higher Risk of Further Vascular Events Among Transient Ischemic Attack Patients With Diffusion-Weighted Imaging Acute Ischemic Lesions. Stroke, 2004, 35, 2313-2319.	1.0	210
12	Oral Citicoline in Acute Ischemic Stroke. Stroke, 2002, 33, 2850-2857.	1.0	205
13	Patterns and Predictors of Early Risk of Recurrence After Transient Ischemic Attack With Respect to Etiologic Subtypes. Stroke, 2007, 38, 3225-3229.	1.0	204
14	Improving the Predictive Accuracy of Recanalization on Stroke Outcome in Patients Treated With Tissue Plasminogen Activator. Stroke, 2004, 35, 151-156.	1.0	202
15	Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage. Stroke, 2004, 35, 1316-1322.	1.0	199
16	Predictors of Early Arterial Reocclusion After Tissue Plasminogen Activator-Induced Recanalization in Acute Ischemic Stroke. Stroke, 2005, 36, 1452-1456.	1.0	199
17	Acute Hyperglycemia State Is Associated With Lower tPA-Induced Recanalization Rates in Stroke Patients. Stroke, 2005, 36, 1705-1709.	1.0	198
18	Differential Pattern of Tissue Plasminogen Activator–Induced Proximal Middle Cerebral Artery Recanalization Among Stroke Subtypes. Stroke, 2004, 35, 486-490.	1.0	178

#	Article	IF	CITATIONS
19	C-Reactive Protein Predicts Further Ischemic Events in First-Ever Transient Ischemic Attack or Stroke Patients With Intracranial Large-Artery Occlusive Disease. Stroke, 2003, 34, 2463-2468.	1.0	171
20	Prediction of Early Neurological Deterioration Using Diffusion- and Perfusion-Weighted Imaging in Hyperacute Middle Cerebral Artery Ischemic Stroke. Stroke, 2002, 33, 2197-2205.	1.0	160
21	Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia, 2020, 40, 1410-1421.	1.8	158
22	Matrix metalloproteinase—9 concentration after spontaneous intracerebral hemorrhage. Journal of Neurosurgery, 2003, 99, 65-70.	0.9	156
23	A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke. Stroke, 2005, 36, 1415-1420.	1.0	146
24	Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. European Journal of Neurology, 2013, 20, 1277-1283.	1.7	142
25	Hyperacute Ischemic Stroke: Middle Cerebral Artery Susceptibility Sign at Echo-planar Gradient-Echo MR Imaging. Radiology, 2004, 232, 466-473.	3.6	138
26	Impact of Admission Hyperglycemia on Stroke Outcome After Thrombolysis. Stroke, 2004, 35, 2493-2498.	1.0	138
27	Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction. Stroke, 2003, 34, 840-848.	1.0	128
28	Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol. Stroke, 2005, 36, 602-606.	1.0	128
29	Admission CT perfusion may overestimate initial infarct core: the ghost infarct core concept. Journal of NeuroInterventional Surgery, 2017, 9, 66-69.	2.0	126
30	Elevated Serum S100B Levels Indicate a Higher Risk of Hemorrhagic Transformation After Thrombolytic Therapy in Acute Stroke. Stroke, 2007, 38, 2491-2495.	1.0	124
31	Difficult catheter access to the occluded vessel during endovascular treatment of acute ischemic stroke is associated with worse clinical outcome. Journal of NeuroInterventional Surgery, 2013, 5, i70-i73.	2.0	121
32	Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 1000-1004.	1.0	119
33	Plasmatic Level of Neuroinflammatory Markers Predict the Extent of Diffusion-Weighted Image Lesions in Hyperacute Stroke. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1403-1407.	2.4	116
34	Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. European Journal of Neurology, 2008, 15, 82-90.	1.7	113
35	Admission Fibrinolytic Profile Is Associated With Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Tissue Plasminogen Activator. Stroke, 2004, 35, 2123-2127.	1.0	111
36	Monitoring intracranial pressure in patients with malignant middle cerebral artery infarction: is it useful?. Journal of Neurosurgery, 2010, 112, 648-657.	0.9	103

#	Article	IF	CITATIONS
37	A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis, 2011, 216, 205-211.	0.4	103
38	Hyperglycemia during Ischemia Rapidly Accelerates Brain Damage in Stroke Patients Treated with tPA. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1616-1622.	2.4	101
39	Diffusion-weighted MR imaging in the acute phase of transient ischemic attacks. American Journal of Neuroradiology, 2002, 23, 77-83.	1.2	100
40	Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. Journal of Vascular Surgery, 2004, 40, 469-475.	0.6	97
41	Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke. Stroke, 2003, 34, 1038-1040.	1.0	96
42	Vascular MMP-9/TIMP-2 and Neuronal MMP-10 Up-Regulation in Human Brain after Stroke: A Combined Laser Microdissection and Protein Array Study. Journal of Proteome Research, 2009, 8, 3191-3197.	1.8	93
43	Extending the Time Window for Endovascular Procedures According to Collateral Pial Circulation. Stroke, 2011, 42, 3465-3469.	1.0	93
44	Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis. Stroke, 2006, 37, 1205-1210.	1.0	90
45	Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis, 2006, 187, 161-169.	0.4	89
46	Progression of Symptomatic Intracranial Large Artery Atherosclerosis Is Associated With a Proinflammatory State and Impaired Fibrinolysis. Stroke, 2008, 39, 1456-1463.	1.0	89
47	Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thrombosis and Haemostasis, 2004, 91, 1146-1151.	1.8	86
48	Recanalization and Reperfusion Therapies for Acute Ischemic Stroke. Cerebrovascular Diseases, 2009, 27, 162-167.	0.8	84
49	Oxidative Stress After Thrombolysis-Induced Reperfusion in Human Stroke. Stroke, 2010, 41, 653-660.	1.0	83
50	Citicoline in Vascular Cognitive Impairment and Vascular Dementia After Stroke. Stroke, 2011, 42, S40-3.	1.0	78
51	Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en España. Revista Espanola De Cardiologia, 2012, 65, 901-910.	0.6	76
52	Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator. Stroke, 2007, 38, 1076-1078.	1.0	75
53	Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: Should all sporadic ALS cases also be screened for SOD1?. Journal of the Neurological Sciences, 2006, 247, 21-28.	0.3	73
54	MMPâ€2/MMPâ€9 Plasma Level and Brain Expression in Cerebral Amyloid Angiopathyâ€Associated Hemorrhagic Stroke. Brain Pathology, 2012, 22, 133-141.	2.1	73

#	Article	IF	CITATIONS
55	Long-Term Treatment with Citicoline May Improve Poststroke Vascular Cognitive Impairment. Cerebrovascular Diseases, 2013, 35, 146-154.	0.8	70
56	Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvascular Research, 2010, 80, 317-323.	1.1	69
57	Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. Journal of Proteomics, 2012, 75, 4758-4765.	1.2	68
58	Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke. Stroke, 2010, 41, 1528-1535.	1.0	66
59	Stroke and Multi-Infarct Dementia as Presenting Symptoms of Giant Cell Arteritis. Medicine (United) Tj ETQq1 1	0.784314 0.4	rgBT /Overloo
60	Bridging Intravenous–Intra-Arterial Rescue Strategy Increases Recanalization and the Likelihood of a Good Outcome in Nonresponder Intravenous Tissue Plasminogen Activator-Treated Patients. Stroke, 2011, 42, 993-997.	1.0	64
61	Inflammation markers and prediction of post-stroke vascular disease recurrence: The MITICO study. Journal of Neurology, 2009, 256, 217-224.	1.8	62
62	The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sciences, 2013, 3, 1395-1414.	1.1	62
63	A panel of biomarkers including caspase-3 and D-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department. Journal of Internal Medicine, 2011, 270, 166-174.	2.7	61
64	Left Atria Strain Is a Surrogate Marker for Detection of Atrial Fibrillation in Cryptogenic Strokes. Stroke, 2014, 45, e164-6.	1.0	61
65	Arterial Stiffness Is Associated With Basal Ganglia Enlarged Perivascular Spaces and Cerebral Small Vessel Disease Load. Stroke, 2018, 49, 1279-1281.	1.0	61
66	Safety Profile of Tissue Plasminogen Activator Treatment Among Stroke Patients Carrying a Common Polymorphism (C-1562T) in the Promoter Region of the Matrix Metalloproteinase-9 Gene. Stroke, 2003, 34, 2851-2855.	1.0	60
67	Diagnóstico y cuantificación del foramen oval permeable. ¿Cuál es la técnica de referencia? Estudio simultáneo con Doppler transcraneal, ecocardiografÃa transtorácica y transesofágica. Revista Espanola De Cardiologia, 2011, 64, 133-139.	0.6	60
68	Serum Low-Density Lipoprotein Cholesterol Level Predicts Hematoma Growth and Clinical Outcome After Acute Intracerebral Hemorrhage. Stroke, 2011, 42, 2447-2452.	1.0	60
69	Outcomes of a Contemporary Cohort of 536 Consecutive Patients With Acute Ischemic Stroke Treated With Endovascular Therapy. Stroke, 2014, 45, 1046-1052.	1.0	60
70	Determinants of Informal Care, Burden, and Risk of Burnout in Caregivers of Stroke Survivors. Stroke, 2018, 49, 140-146.	1.0	60
71	MRI findings in aphasic status epilepticus. Epilepsia, 2008, 49, 1465-1469.	2.6	59
72	Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1984-1996.	0.7	59

#	Article	IF	CITATIONS
73	Economic impact of patients admitted to stroke units in Spain. European Journal of Health Economics, 2017, 18, 449-458.	1.4	59
74	Plasma S100B Level After Acute Spontaneous Intracerebral Hemorrhage. Stroke, 2006, 37, 2837-2839.	1.0	58
75	Baseline National Institutes of Health Stroke Scale–Adjusted Time Window for Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke. Stroke, 2014, 45, 1059-1063.	1.0	58
76	Lack of Evidence for Arterial Ischemia in Transient Global Amnesia. Stroke, 2008, 39, 476-479.	1.0	56
77	Transcranial Duplex Sonography for Monitoring Hyperacute Intracerebral Hemorrhage. Stroke, 2009, 40, 987-990.	1.0	55
78	Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients. Stroke, 2006, 37, 2288-2293.	1.0	54
79	Association of a Genetic Variant in the <i>ALOX5AP</i> with Higher Risk of Ischemic Stroke: A Case-Control, Meta-Analysis and Functional Study. Cerebrovascular Diseases, 2010, 29, 528-537.	0.8	54
80	Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study). Cephalalgia, 2019, 39, 91-99.	1.8	54
81	Seizures after Ischemic Stroke: A Matched Multicenter Study. Annals of Neurology, 2021, 90, 808-820.	2.8	54
82	Do Bubble Characteristics Affect Recanalization in Stroke Patients Treated with Microbubble-Enhanced Sonothrombolysis?. Ultrasound in Medicine and Biology, 2008, 34, 1573-1577.	0.7	53
83	Angiogenesis in Symptomatic Intracranial Atherosclerosis. Stroke, 2005, 36, 92-97.	1.0	52
84	Transcranial Doppler Monitoring of Transcervical Carotid Stenting With Flow Reversal Protection. Stroke, 2006, 37, 2846-2849.	1.0	50
85	Influence of thrombinâ€activatable fibrinolysis inhibitor and plasminogen activator inhibitorâ€1 gene polymorphisms on tissueâ€type plasminogen activatorâ€induced recanalization in ischemic stroke patients. Journal of Thrombosis and Haemostasis, 2007, 5, 1862-1868.	1.9	49
86	Impact of Time to Treatment on Tissue-Type Plasminogen Activator–Induced Recanalization in Acute Ischemic Stroke. Stroke, 2014, 45, 2734-2738.	1.0	49
87	<i>PATJ</i> Low Frequency Variants Are Associated With Worse Ischemic Stroke Functional Outcome. Circulation Research, 2019, 124, 114-120.	2.0	49
88	Differentiated clinical presentation of early and late-onset Alzheimer's disease: is 65Âyears of age providing a reliable threshold?. Journal of Neurology, 2015, 262, 1238-1246.	1.8	47
89	Silent Myocardial Ischemia in Patients With Symptomatic Intracranial Atherosclerosis. Stroke, 2005, 36, 1201-1206.	1.0	46
90	Speed of tPA-Induced Clot Lysis Predicts DWI Lesion Evolution in Acute Stroke. Stroke, 2007, 38, 955-960.	1.0	46

#	Article	IF	CITATIONS
91	Triflusal for preventing serious vascular events in people at high risk. The Cochrane Library, 2005, , CD004296.	1.5	45
92	C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurologica Scandinavica, 2007, 115, 60-66.	1.0	44
93	Impact of a telemedicine system on acute stroke care in a community hospital. Journal of Telemedicine and Telecare, 2009, 15, 260-263.	1.4	44
94	Age-adjusted infarct volume threshold for good outcome after endovascular treatment. Journal of NeuroInterventional Surgery, 2014, 6, 418-422.	2.0	43
95	Plasma β-Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke. Neurodegenerative Diseases, 2012, 10, 320-323.	0.8	41
96	VAP-1/SSAO Plasma Activity and Brain Expression in Human Hemorrhagic Stroke. Cerebrovascular Diseases, 2012, 33, 55-63.	0.8	41
97	Investigating silent strokes in hypertensives: a magnetic resonance imaging study (ISSYS): rationale and protocol design. BMC Neurology, 2013, 13, 130.	0.8	41
98	Mechanical Thrombectomy in and Outside the REVASCAT Trial. Stroke, 2015, 46, 3437-3442.	1.0	41
99	Is it Time to Reassess the SITS-MOST Criteria for Thrombolysis?. Stroke, 2009, 40, 2568-2571.	1.0	40
100	Trevo versus Solitaire a Headâ€ŧoâ€Head Comparison Between Two Heavy Weights of Clot Retrieval. Journal of Neuroimaging, 2014, 24, 167-170.	1.0	40
101	Citicoline in Intracerebral Haemorrhage: A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Pilot Study. Cerebrovascular Diseases, 2006, 21, 380-385.	0.8	39
102	Fas System Activation in Perihematomal Areas After Spontaneous Intracerebral Hemorrhage. Stroke, 2008, 39, 1730-1734.	1.0	39
103	Ischemic Core Overestimation on Computed Tomography Perfusion. Stroke, 2021, 52, 1751-1760.	1.0	39
104	Transcervical carotid stenting with flow reversal protection: Experience in high-risk patients. Journal of Vascular Surgery, 2007, 46, 49-54.	0.6	38
105	Thrombolysis in Anterior Versus Posterior Circulation Strokes: Timing of Recanalization, Ischemic Tolerance, and Other Differences. , 2011, 21, 108-112.		38
106	Basic Mechanisms in Intracranial Large-Artery Atherosclerosis: Advances and Challenges. Cerebrovascular Diseases, 2005, 20, 75-83.	0.8	37
107	Stroke Patients With Cardiac Atrial Septal Abnormalities: Differential Infarct Patterns on DWI. Journal of Neuroimaging, 2006, 16, 334-340.	1.0	37
108	Transcervical carotid stenting with flow reversal is a safe technique for high-risk patients older than 70 years. Journal of Vascular Surgery, 2012, 55, 978-984.	0.6	37

#	Article	IF	CITATIONS
109	Mitral papillary fibroelastoma as a cause of cardiogenic embolic stroke: report of two cases and review of the literature. European Journal of Neurology, 2000, 7, 449-453.	1.7	36
110	Accuracy of Serial National Institutes of Health Stroke Scale Scores to Identify Artery Status in Acute Ischemic Stroke. Circulation, 2007, 115, 2660-2665.	1.6	36
111	Absence of Usefulness of ABCD Score in the Early Risk of Stroke of Transient Ischemic Attack Patients. Stroke, 2007, 38, 855-856.	1.0	36
112	Caspase-3 is related to infarct growth after human ischemic stroke. Neuroscience Letters, 2008, 430, 1-6.	1.0	36
113	Intraâ€arterial Administration of Microbubbles and Continuous 2â€MHz Ultrasound Insonation to Enhance Intraâ€arterial Thrombolysis. Journal of Neuroimaging, 2010, 20, 224-227.	1.0	36
114	Therapeutic Interventions and Success in Risk Factor Control for Secondary Prevention of Stroke. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 460-465.	0.7	36
115	Lipoprotein-Associated Phospholipase A ₂ Activity Is Associated with Large-Artery Atherosclerotic Etiology and Recurrent Stroke in TIA Patients. Cerebrovascular Diseases, 2012, 33, 150-158.	0.8	36
116	Outcomes measured by mortality rates, quality of life and degree of autonomy in the first year in stroke units in Spain. Health and Quality of Life Outcomes, 2015, 13, 36.	1.0	36
117	Selecting the target and the message for a stroke public education campaign: a local survey conducted by neurologists. European Journal of Epidemiology, 2001, 17, 581-586.	2.5	35
118	Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheterization and Cardiovascular Interventions, 2003, 60, 540-542.	0.7	35
119	Impact of Telemedicine on Acute Management of Stroke Patients Undergoing Endovascular Procedures. Cerebrovascular Diseases, 2012, 34, 436-442.	0.8	35
120	Recurrent transient ischaemic attack and early risk of stroke: data from the PROMAPA study. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 596-603.	0.9	35
121	Outcomes of Intravenous Thrombolysis After Dissemination of the Stroke Code and Designation of New Referral Hospitals in Catalonia. Stroke, 2011, 42, 2001-2006.	1.0	34
122	Timing of Recanalization After Microbubble-Enhanced Intravenous Thrombolysis in Basilar Artery Occlusion. Stroke, 2007, 38, 2931-2934.	1.0	33
123	Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin. Journal of Neurology, 2012, 259, 2538-2545.	1.8	33
124	Brain Natriuretic Peptide Is Associated with Worsening and Mortality in Acute Stroke Patients but Adds No Prognostic Value to Clinical Predictors of Outcome. Cerebrovascular Diseases, 2012, 34, 240-245.	0.8	32
125	Longâ€ŧerm safety and effectiveness of levodopaâ€carbidopa intestinal gel infusion. Brain and Behavior, 2017, 7, e00758.	1.0	32
126	Comparison of the impact of atrial fibrillation on the risk of early death after stroke in women versus men. Journal of Neurology, 2006, 253, 1484-1489.	1.8	31

#	Article	IF	CITATIONS
127	Transcervical carotid stenting with flow reversal is safe in octogenarians: A preliminary safety study. Journal of Vascular Surgery, 2008, 47, 96-100.	0.6	31
128	Predictors of Tissue-Type Plasminogen Activator Nonresponders According to Location of Vessel Occlusion. Stroke, 2012, 43, 417-421.	1.0	31
129	Prevalence and Associated Factors of Silent Brain Infarcts in a Mediterranean Cohort of Hypertensives. Hypertension, 2014, 64, 658-663.	1.3	30
130	Quantitative Evaluation of Striatal I-123-FP-CIT Uptake in Essential Tremor and Parkinsonism. Clinical Nuclear Medicine, 2011, 36, 991-996.	0.7	29
131	Geographic Differences in Acute Stroke Care in Catalunya: Impact of a Regional Interhospital Network. Cerebrovascular Diseases, 2008, 26, 284-288.	0.8	28
132	Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke. International Journal of Molecular Sciences, 2016, 17, 390.	1.8	27
133	Blood biomarkers predictive of epilepsy after an acute stroke event. Epilepsia, 2020, 61, 2244-2253.	2.6	27
134	Trevo System: Singleâ€Center Experience with a Novel Mechanical Thrombectomy Device. Journal of Neuroimaging, 2013, 23, 7-11.	1.0	25
135	Predicting Atrial Fibrillation with High Risk of Embolization with Atrial Strain and NT-proBNP. Translational Stroke Research, 2021, 12, 735-741.	2.3	25
136	Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis, 2011, 218, 181-187.	0.4	24
137	Leukoaraiosis is associated with genes regulating blood-brain barrier homeostasis in ischaemic stroke patients. European Journal of Neurology, 2011, 18, 826-835.	1.7	24
138	The impact of post-stroke complications on in-hospital mortality depends on stroke severity. European Stroke Journal, 2017, 2, 54-63.	2.7	24
139	ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters, 2006, 398, 167-171.	1.0	23
140	Endogenous Activated Protein C Predicts Hemorrhagic Transformation and Mortality after Tissue Plasminogen Activator Treatment in Stroke Patients. Cerebrovascular Diseases, 2009, 28, 143-150.	0.8	23
141	Osteopontin predicts long-term functional outcome among ischemic stroke patients. Journal of Neurology, 2011, 258, 486-493.	1.8	23
142	GRECOS Project (Genotyping Recurrence Risk of Stroke). Stroke, 2017, 48, 1147-1153.	1.0	23
143	C-Reactive Protein Gene C1444T Polymorphism and Risk of Recurrent Ischemic Events in Patients with Symptomatic Intracranial Atherostenoses. Cerebrovascular Diseases, 2009, 28, 95-102.	0.8	22
144	ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiology of Aging, 2011, 32, 551.e13-551.e22.	1.5	22

#	Article	IF	CITATIONS
145	Obstructive sleep apnea and silent cerebral infarction in hypertensive individuals. Journal of Sleep Research, 2018, 27, 232-239.	1.7	22
146	Reversible hemichorea associated with extracranial carotid artery stenosis. Journal of the Neurological Sciences, 2011, 300, 185-186.	0.3	21
147	Headache in Cerebral Hemorrhage Is Associated With Inflammatory Markers and Higher Residual Cavity. Headache, 2005, 45, 1236-1243.	1.8	20
148	Cognitive Improvement in Patients with Severe Carotid Artery Stenosis after Transcervical Stenting with Protective Flow Reversal. Cerebrovascular Diseases, 2013, 35, 124-130.	0.8	20
149	Candidate-gene association study searching for genetic factors involved in migraine chronification. Cephalalgia, 2015, 35, 500-507.	1.8	20
150	Long-term epilepsy after early post-stroke status epilepticus. Seizure: the Journal of the British Epilepsy Association, 2019, 69, 193-197.	0.9	20
151	Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thrombosis and Haemostasis, 2009, 102, 759-764.	1.8	19
152	The I/D polymorphism of the ACE1 gene is not associated with ischaemic stroke in Spanish individuals. European Journal of Neurology, 2010, 17, 1390-1392.	1.7	18
153	Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. Pharmacogenomics, 2013, 14, 495-504.	0.6	18
154	Stentrievers versus other endovascular treatment methods for acute stroke: comparison of procedural results and their relationship to outcomes. Journal of NeuroInterventional Surgery, 2014, 6, 265-269.	2.0	18
155	Assessment of enlarged perivascular spaces and their relation to target organ damage and mild cognitive impairment in patients with hypertension. European Journal of Neurology, 2016, 23, 1044-1050.	1.7	18
156	Leptomeningeal Collateral Flow Modifies Endovascular Treatment Efficacy on Large-Vessel Occlusion Strokes. Stroke, 2021, 52, 299-303.	1.0	18
157	Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome. Current Neurovascular Research, 2009, 6, 246-251.	0.4	18
158	Correlation of blood biomarkers with early-onset seizures after an acute stroke event. Epilepsy and Behavior, 2020, 104, 106549.	0.9	17
159	<i>CD40</i> -1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics, 2010, 11, 763-772.	0.6	16
160	Decreased Levels of Angiogenic Growth Factors in Intracranial Atherosclerotic Disease despite Severity-Related Increase in Endothelial Progenitor Cell Counts. Cerebrovascular Diseases, 2013, 35, 81-88.	0.8	16
161	Immunological Biomarkers Improve the Accuracy of Clinical Risk Models of Infection in the Acute Phase of Ischemic Stroke. Cerebrovascular Diseases, 2013, 35, 220-227.	0.8	15
162	Short and Midâ€Term Predictors of Response to OnabotulinumtoxinA: Realâ€Life Experience Observational Study. Headache, 2020, 60, 677-685.	1.8	15

#	Article	IF	CITATIONS
163	Cryptogenic Stroke, Aortic Arch Atheroma and Patent Foramen Ovale. Cerebrovascular Diseases, 2007, 24, 84-88.	0.8	14
164	Preferential Effect of Premorbid Statins on Atherothrombotic Strokes through Collateral Circulation Enhancement. European Neurology, 2012, 68, 171-176.	0.6	14
165	Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. Atherosclerosis, 2012, 220, 532-536.	0.4	14
166	Blood pressure in the initial phase of acute ischaemic stroke: Evolution and its role as an independent prognosis factor at discharge and after 3 months of followâ€up. Blood Pressure, 2008, 17, 284-290.	0.7	13
167	Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients. Stroke, 2012, 43, 1398-1400.	1.0	13
168	Cognitive assessment protocol design in the ISSYS (Investigating Silent Strokes in hYpertensives: A) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf 5
169	Genome-Wide Association Study of White Blood Cell Counts in Patients With Ischemic Stroke. Stroke, 2019, 50, 3618-3621.	1.0	13
170	Unexpected I-123 FP-CIT Uptake in a Brain Tumor. Clinical Nuclear Medicine, 2009, 34, 608-609.	0.7	11
171	Prognostic Value of Plasma Chitotriosidase Activity in Acute Stroke Patients. International Journal of Stroke, 2014, 9, 910-916.	2.9	10
172	Fluorescent Molecular Peroxidation Products. Stroke, 2014, 45, 432-437.	1.0	10
173	Triflusal and Aspirin in the Secondary Prevention of Atherothrombotic Ischemic Stroke: A Very Long-Term Follow-Up. Cerebrovascular Diseases, 2014, 37, 181-187.	0.8	10
174	Parkinsonism related to Percheron artery infarct. Journal of the Neurological Sciences, 2017, 373, 21-22.	0.3	10
175	Single nucleotide variations in <i>ZBTB46</i> are associated with post-thrombolytic parenchymal haematoma. Brain, 2021, 144, 2416-2426.	3.7	10
176	Reperfusion Therapy for Acute Stroke Improves Outcome by Decreasing Neuroinflammation. Translational Stroke Research, 2010, 1, 261-267.	2.3	9
177	Stroke after prolonged air travel associated with a pulmonary arteriovenous malformation. Journal of the Neurological Sciences, 2010, 292, 99-100.	0.3	9
178	Low ankleâ^'brachial index predicts new vascular events and functional outcome after 1Âyear in patients with nonâ€cardioembolic stroke: our experience and review. European Journal of Neurology, 2014, 21, 100-106.	1.7	9
179	Monocyte-to-Lymphocyte Ratio in Clot Analysis as a Marker of Cardioembolic Stroke Etiology. Translational Stroke Research, 2022, 13, 949-958.	2.3	9
180	No evidence of <i>APP</i> point mutation and locus duplication in individuals with cerebral amyloid angiopathy. European Journal of Neurology, 2011, 18, 1279-1281.	1.7	8

#	Article	IF	CITATIONS
181	Ischemic Stroke Outcome and Early Infection: Its Deleterious Effect Seems to Operate Also among Tissue Plasminogen Activator-Treated Patients. European Neurology, 2011, 65, 82-87.	0.6	8
182	Incidence and mortality in adults with epilepsy in northern Spain. Acta Neurologica Scandinavica, 2021, 143, 27-33.	1.0	8
183	Mediumâ€ŧerm effects of COVIDâ€19 pandemic on epilepsy: A followâ€up study. Acta Neurologica Scandinavica, 2021, 144, 99-108.	1.0	8
184	GEMFIBROZIL-INDUCED HEADACHE. Lancet, The, 1988, 332, 1246.	6.3	7
185	â€~Herald hemiparesis' of basilar artery occlusion: early recognition by transcranial Doppler ultrasound. European Journal of Neurology, 2000, 7, 91-93.	1.7	7
186	Neuroprotection in Malignant MCA Infarction. Cerebrovascular Diseases, 2006, 21, 99-105.	0.8	7
187	Arterial Blood Gas Analysis of Samples Directly Obtained Beyond Cerebral Arterial Occlusion During Endovascular Procedures Predicts Clinical Outcome. Journal of Neuroimaging, 2013, 23, 180-184.	1.0	7
188	Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke. Life, 2021, 11, 135.	1.1	7
189	Buying Time for Recanalization in Acute Stroke: Arterial Blood Infusion Beyond the Occluding Clot as a Neuroprotective Strategy. Journal of Neuroimaging, 2009, 19, 188-190.	1.0	6
190	Selecting Endovascular Treatment Strategy according to the Location of Intracranial Occlusion in Acute Stroke. Cerebrovascular Diseases, 2013, 35, 502-506.	0.8	6
191	Predictive value of ankle-brachial index and PAI-1 in symptomatic intracranial atherosclerotic disease recurrence. Atherosclerosis, 2014, 233, 186-189.	0.4	6
192	The Role of Echocardiography Screening at the Stroke Unit. Frontiers in Neurology, 2020, 11, 1003.	1.1	6
193	RP11-362K2.2:RP11-767I20.1 Genetic Variation Is Associated with Post-Reperfusion Therapy Parenchymal Hematoma. A GWAS Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 3137.	1.0	6
194	The economic burden of newly diagnosed epilepsy in Spain. Epilepsy and Behavior, 2021, 125, 108395.	0.9	6
195	Potential Blood Pressure Thresholds and Outcome in Acute Intracerebral Hemorrhage. European Neurology, 2014, 72, 203-208.	0.6	5
196	Monitoring of Cortical Activity Postreperfusion. A Powerful Tool for Predicting Clinical Response Immediately After Recanalization. Journal of Neuroimaging, 2015, 25, 257-262.	1.0	5
197	Dementia Rating Scale-2 normative data for middle-and older-aged Castilian speaking Spaniards. Clinical Neuropsychologist, 2016, 30, 1443-1456.	1.5	5
198	Molecular Signatures of Course and Prognosis of Intracerebral Hemorrhage. Seminars in Cerebrovascular Diseases and Stroke, 2005, 5, 178-188.	0.1	4

#	Article	IF	CITATIONS
199	Sleep Quality and Levodopa Intestinal Gel Infusion in Parkinson's Disease: A Pilot Study. Parkinson's Disease, 2018, 2018, 1-6.	0.6	4
200	Triflusal and Aspirin Have Different Effects on Inflammatory Biomarkers Measured in Patients with Acute Ischemic Stroke. Cerebrovascular Diseases, 2009, 28, 371-377.	0.8	3
201	Stroke Echoscan Protocol: A Fast and Accurate Pathway to Diagnose Embolic Strokes. Journal of Neuroimaging, 2015, 25, 365-369.	1.0	3
202	Screening of Embolic Sources by Point-of-Care Ultrasound in the Acute Phase of Ischemic Stroke. Ultrasound in Medicine and Biology, 2020, 46, 2173-2180.	0.7	3
203	Thumb-up sign: Characterization of an undescribed seizure semiologic sign. Seizure: the Journal of the British Epilepsy Association, 2021, 89, 62-64.	0.9	3
204	Nighttime hypoxia affects global cognition, memory, and executive function in community-dwelling individuals with hypertension. Journal of Clinical Sleep Medicine, 2020, 16, 243-250.	1.4	3
205	Real-time monitoring of recanalization after intravenous thrombolysis for acute ischemic stroke. European Journal of Neurology, 2006, 13, 426-427.	1.7	2
206	Effect of late-onset epilepsy on cognitive functioning in patients with small vessel disease. Epilepsy and Behavior, 2021, 123, 108238.	0.9	2
207	Interictal brain activity changes in temporal lobe epilepsy: A quantitative electroencephalogram analysis. Acta Neurologica Scandinavica, 2021, 145, 239.	1.0	2
208	P2â€333: FRONTOTEMPORAL LOBE DEGENERATION ASSOCIATED WITH TDPâ€43 PROTEINOPATHY PRESENTING A CORTICOBASAL SYNDROME: A CASE WITH PATHOLOGICAL CONFIRMATION. Alzheimer's and Dementia, 2018, 14, P809.	AS 0.4	0
209	ArteriopatÃa cerebral progresiva de inicio tardÃo posradioterapia por glioma de quiasma óptico. Medicina ClÂnica, 2004, 123, 279-279.	0.3	0